ArticleJournal of the American Heart Association2018
ADP Platelet Hyperreactivity Predicts Cardiovascular Disease in the FHS (Framingham Heart Study).
Article in Journal of the American Heart Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 80 citations in OpenAlex.
- The efficacy of aspirin to inhibit platelet aggregation in patients hospitalised with a severe infection: a multicentre, open-label, randomised controlled trial.Clinical and experimental medicine · 2023Trial
- Association of Platelet Aggregation With Markers of Alzheimer Disease Pathology in Middle-Aged Participants of the Framingham Heart Study.Neurology · 2025Article
- Dietary Fat Intake and Indices of Blood Profiles in High-Performance Athletes: An Exploratory Study Focusing on Platelet Variables.Nutrients · 2025Article
- Insulin resistance in type 1 diabetes is a key modulator of platelet hyperreactivity.Diabetologia · 2025Article
- Functional Foods in Preventing Human Blood Platelet Hyperactivity-Mediated Diseases-An Updated Review.Nutrients · 2024Review
- Integrated microfluidic multiple electrode aggregometry for point-of-care platelet function analysis.Lab on a chip · 2024Article
- One immune cell to bind them all: platelet contribution to neurodegenerative disease.Molecular neurodegeneration · 2024Review
- A Platelet Reactivity ExpreSsion Score derived from patients with peripheral artery disease predicts cardiovascular risk.Nature communications · 2024Observational
- Cardiovascular and genetic determinants of platelet high responsiveness: results from the Gutenberg Health Study.Blood advances · 2024Article
- Obstructive Sleep Apnea, Platelet Aggregation, and Cardiovascular Risk.Journal of the American Heart Association · 2024Article
- G protein-coupled receptor kinase 5 regulates thrombin signaling in platelets.Research and practice in thrombosis and haemostasis · 2024Article
- Factors that modulate platelet reactivity as measured by 5 assay platforms in 3429 individuals.Research and practice in thrombosis and haemostasis · 2024Article
- Mitofusin-2 Regulates Platelet Mitochondria and Function.Circulation research · 2024Article
- Berberine Decreases Thrombosis Potential Induced by a High-choline Diet by Inhibiting CutC Enzyme.Current medicinal chemistry · 2024Article
- Article
- Platelet Reactivity and Cardiovascular Mortality Risk in the LURIC Study.Journal of clinical medicine · 2023Article
- The Relationship Between Premature Adrenarche and Platelet AggregationJournal of clinical research in pediatric endocrinology · 2023Article
- Appraisal of Cardiovascular Risk Factors, Biomarkers, and Ocular Imaging in Cardiovascular Risk Prediction.Current cardiology reviews · 2023Review
- Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach.Arteriosclerosis, thrombosis, and vascular biology · 2022Article
- Hormones, age, and sex affect platelet responsiveness in vitro.Transfusion · 2022Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundPlatelet function is associated with adverse events in patients with cardiovascular disease (CVD). METHODS AND
resultsWe examined associations of baseline platelet function with incident CVD events in the community-based FHS (Framingham Heart Study). Participants free of prevalent CVD and without recent aspirin treatment with available data in the Framingham Offspring cohort (1991-1995) and Omni cohort (1994-1998) were included. Platelet function was measured with light transmission aggregometry using collagen (1.9 μg/mL), ADP (0.05-15 μmol/L), and epinephrine (0.01-15 μmol/L). We used proportional hazards models to analyze incident outcomes (myocardial infarction/stroke, CVD, and CVD mortality) with respect to platelet measures. The study sample included 2831 participants (average age, 54.3 years; 57% women). During follow-up (median, 20.4 years), we observed 191 composite incident myocardial infarction or stroke events, 432 incident CVD cases, and 117 CVD deaths. Hyperreactivity to ADP and platelet aggregation at ADP concentration of 1.0 μmol/L were significantly associated with incident myocardial infarction/stroke in a multivariable model (hazard ratio, 1.68 [95% confidence interval, 1.13-2.50] [
conclusionsIntrinsic hyperreactivity to low-dose ADP in our community-based sample, who were free of CVD and any antiplatelet therapy, is associated with future arterial thrombosis during a 20-year follow-up. These findings reinforce ADP activation inhibition as a critical treatment paradigm and encourage further study of ADP inhibitor-refractive populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.